Inhibition of IL signaling also has been developed against autoimmune diseases, such as IL-1R antagonist (Anakinra), IL-1R1-IgG Fc (Rilonacept), anti-IL-1β mAb (Canakinumab), anti-IL-6 mAb (Sirukumab, Olokizumab, Clazakizumab, and Siltuximab), anti-IL-6R mAb (Tocilizumab, Sarilumab, and Vobarilizumab), anti-IL-17 mAb (Ixekizumab and Secukinumab), anti-IL-17R mAb (Brodalumab), anti-IL17A/F mAb (Bimekizumab), anti-IL-23/p40 mAb (Ustekinumab) and anti-IL-23/p19 mAb (Guselkumab, Risankizumab, Tildrakizumab, and Mirikizumab). The gene discussed is IL1R1; the disease is autoimmune disease.